DBV Technologies (France) Profile

EUR 0.50  1.58%

DBV Technologies Summary

DBV Technologies S A (DBV) is traded on Paris Stock Exchange in France. It is located in 177-181 avenue Pierre Brossolette and employs 244 people. The company currently falls under 'Small-Cap' category with current market capitalization of 931.84 M. DBV Technologies S A operates under Healthcare sector and is part of Pharmaceuticals And Biosciences industry. This company has 29.98 M outstanding shares. DBV TECHNOLOGIES has accumulated about 137.88 M in cash with (114.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.52.
Check DBV Technologies Probability Of Bankruptcy

Target Price Odds Analysis

Odds Below 32.06HorizonTargetOdds Above 32.06
85.33%30 days 32.06 14.50%
Based on normal probability distribution, the odds of DBV Technologies to move above current price in 30 days from now is about 14.5% (This DBV Technologies S A probability density function shows the probability of DBV Technologies Stock to fall within a particular range of prices over 30 days) .

Top Holders

DBV Technologies S Risk Profiles

Key Fundamentals

Current Ratings

DBV Technologies 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for DBV Technologies S A are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France. DBV Technologies operates under Biotechnology classification in France and traded on Paris Stock Exchange. It employs 244 people. more
NameDBV Technologies S A
Chairman of the Board, CEOPierreHenri BenhamouView All
Macroaxis Advice
Healthcare, Pharmaceuticals And Biosciences
InstrumentFrance Stock View All
Business Address177-181 avenue Pierre Brossolette
Foreign Associates
ExchangeParis Stock Exchange
IndustryPharmaceuticals And Biosciences
Phone33 1 55 42 78 78
CurrencyEUR - Euro


DBV Technologies Corporate Directors
Rafaele Tordjman Director - Representative of Sofinnova Partners
Pascale Ehouarn Industrial Development and Production Director
Claude Thebault Medical Director
Additionally see Investing Opportunities. Please also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.